It May Be Time to Buy Shares of Teva Pharma (NYSE:TEVA) as Goldman Sachs Has Upgraded The Stock

June 26, 2018 - By Henry Gaston

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Teva Pharma (NYSE:TEVA) Stock Upgrade

In a research note revealed to investors and clients earlier today, Goldman Sachs increased shares of Teva Pharma (NYSE:TEVA) to a Buy. Analysts currently have a $28.0000 target on the shares. Goldman Sachs’s target indicates a ppossible upside of 18.80 % from the previous close of the stock.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 19 analysts covering Teva Pharma (NYSE:TEVA), 5 have Buy rating, 3 Sell and 11 Hold. Therefore 26% are positive. Teva Pharma has $2800 highest and $13.0 lowest target. $19.68’s average target is -16.50% below currents $23.57 stock price. Teva Pharma had 37 analyst reports since January 2, 2018 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, January 23 by Oppenheimer. Deutsche Bank maintained the shares of TEVA in report on Friday, February 9 with “Hold” rating. The firm has “Hold” rating given on Wednesday, January 31 by Guggenheim. The firm earned “Hold” rating on Thursday, February 8 by Cowen & Co. Wells Fargo maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Thursday, May 3. Wells Fargo has “Sell” rating and $16.5000 target. The rating was upgraded by Citigroup on Thursday, January 4 to “Buy”. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) earned “Hold” rating by Guggenheim on Tuesday, March 13. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Buy” rating given on Thursday, January 25 by Susquehanna. The firm has “Hold” rating by RBC Capital Markets given on Sunday, March 25. Guggenheim maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Thursday, May 24 with “Hold” rating.

The stock decreased 1.75% or $0.42 during the last trading session, reaching $23.57. About 8.45M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 22.74% since June 26, 2017 and is downtrending. It has underperformed by 35.31% the S&P500.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on August, 2. They expect $0.62 earnings per share, down 37.37 % or $0.37 from last year’s $0.99 per share. TEVA’s profit will be $631.47 million for 9.50 P/E if the $0.62 EPS becomes a reality. After $0.91 actual earnings per share reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -31.87 % negative EPS growth.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $24.01 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: which released: “Teva Pharma’s (TEVA) Favorable Ruling in Bendeka ODE Case Extends Revenue Stream – Citi” on June 11, 2018, also Globes.Co.Il with their article: “Negative trial result hardly dents Teva share price” published on June 17, 2018, Globes.Co.Il published: “Sun: Resurgent Teva fails to lift flat TASE” on June 10, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Globes.Co.Il and their article: “Teva well on the road to recovery” published on June 13, 2018 as well as‘s news article titled: “Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play” with publication date: June 15, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.